Aurobindo Pharma Ltd on Wednesday reported a 26 percent increase in consolidated net profit at Rs 805.65 crore in the second quarter ended September.
The company had posted a consolidated net profit of Rs 639.53 crore in the same quarter last fiscal, Aurobindo Pharma said in a regulatory filing.
Consolidated total revenue from operations during the period under review stood at 15.8 per cent year-on-year (YoY) Rs 6,483.44 crore it added.
The stock was trading at Rs 860.50, up to Rs 50.40, or 6.21 per cent at 11:09 hours. It has touched an intraday high of Rs 864.00 and an intraday low of Rs 800.00.
The company’s managing director N Govindarajan said “We continue to perform well across all our key geographies and segments to report a consistent set of earnings. We are happy to state that we have completed phase I clinical trials for our first biosimilar and started trials for three more products”.
“On our endeavor towards our differentiated products basket, we are happy to state that we have completed phase clinical trials for our first biosimilar and started trials for three more products. We reiterate that we are committed to resolving all pending regulatory issues,” he added.
Its board has also approved a second interim dividend of 125 per cent at Rs 1.25 per equity share of Rs 1 for the financial year 2020-21.